Cargando…
The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome
Multiple sclerosis (MS) is a clinically heterogenous disease. Currently, we cannot identify patients with more active disease who may potentially benefit from earlier interventions. Previous data from our lab identified the CXCL13 index (I(CXCL13)), a measure of intrathecal production of CXCL13, as...
Autores principales: | Pike, Steven C., Gilli, Francesca, Pachner, Andrew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341709/ https://www.ncbi.nlm.nih.gov/pubmed/37446228 http://dx.doi.org/10.3390/ijms241311050 |
Ejemplares similares
-
Intrathecally produced CXCL13: A predictive biomarker in multiple sclerosis
por: DiSano, Krista D, et al.
Publicado: (2020) -
Are CSF CXCL13 concentrations solely dependent on intrathecal production? A commentary on “Chemokine CXCL13 in serum, CSF, and blood–CSF barrier function”
por: DiSano, Krista D., et al.
Publicado: (2021) -
The Brave New World of Early Treatment of Multiple Sclerosis: Using the Molecular Biomarkers CXCL13 and Neurofilament Light to Optimize Immunotherapy
por: Pachner, Andrew
Publicado: (2022) -
High-Resolution Diffusion Tensor Spinal Cord MRI Measures as Biomarkers of Disability Progression in a Rodent Model of Progressive Multiple Sclerosis
por: Gilli, Francesca, et al.
Publicado: (2016) -
Divergent complement system activation in two clinically distinct murine models of multiple sclerosis
por: Linzey, Michael, et al.
Publicado: (2022)